Core Insights - Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections, specifically through its product Decoy20 [1][5] - The company has enrolled over 20 patients in the weekly dosing cohort of its Phase 1 trial for Decoy20, achieving a significant milestone [2] - Initial findings indicate that Decoy20 at a dosage of 30 million cells is well-tolerated, showing a favorable safety profile and early signs of clinical benefit, including stable disease in some patients [2] - Decoy20 treatment has resulted in short-term increases in key immune system biomarkers, indicating activation of the body's defenses against cancer [2][3] - The treatment also promotes broad immune cell trafficking, suggesting active mobilization of immune cells from bone marrow to tissues, which is a critical pharmacodynamic marker [3][4] - The company is exploring the combination of Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, in a new arm of its Phase 1b/2 clinical trial to assess safety and preliminary anti-tumor activity [4] Company Overview - Indaptus Therapeutics leverages over a century of immunotherapy advancements, focusing on activating both innate and adaptive immune responses through a multi-targeted approach [6] - The Decoy platform utilizes non-pathogenic Gram-negative bacteria to produce immune system-activating signals, aiming to enhance the effectiveness of existing cancer treatments [6] - Pre-clinical studies have shown that Decoy product candidates can eradicate tumors and produce significant activity against chronic viral infections like hepatitis B and HIV [6]
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20